CAR-T 细胞疗法治疗胶质母细胞瘤的安全性和疗效：一项系统性综述和荟萃分析

Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy for Glioblastoma: A Systemic Review and Meta-Analysis.

尽管 CAR-T 细胞疗法在胶质母细胞瘤患者中是一种相对安全的治疗选择，但其疗效有限，提示有必要进一步研究以将其转化为复发性胶质母细胞瘤治疗的临床实践。

优化基于 CAR-T 细胞的治疗策略以增强胶质母细胞瘤治疗抗肿瘤疗效的研究进展

Advances in the Optimization of CAR-T-Cell-Based Therapeutic Approaches to Enhance Antitumor Efficacy in Glioblastoma Treatment.

表达 IL7/CCL19 的 CAR-T 细胞在胶质母细胞瘤和胰腺癌难治性实体瘤模型中的治疗疗效

Therapeutic Efficacy of IL7/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer.

NK 细胞疫苗在实体瘤临床试验中的优势：多种生物学策略与技术的实施

The advantages of NK cell vaccines in solid carcinoma clinical trials: conducted by various biology strategy and technology.

NLGN4X TCR 转基因 T 细胞治疗胶质瘤

NLGN4X TCR transgenic T cells to treat gliomas.

NLGN4X-TCR-T 在临床前胶质母细胞瘤模型中显示出疗效。

超越 CAR-T 细胞：探索 CAR-NK、CAR-M 与 CAR-γδ T 策略在实体瘤免疫治疗中的应用

Beyond CAR-T Cells: exploring CAR-NK, CAR-M, and CAR-γδ T strategies in solid tumor immunotherapy.

体外及卵巢癌小鼠异种移植模型中对胶质母细胞瘤、乳腺癌和胰腺癌有效的嵌合抗原受体 (CAR)-NK92 细胞

Chimeric Antigen Receptor (CAR)-NK92 cells effective against glioblastoma, breast- and pancreatic cancer in vitro and in a murine xenograft model of o

我们的结果表明，CD44v6-CAR-NK92 细胞可能是一种有吸引力的治疗实体瘤的治疗剂。

肿瘤治疗中声动力疗法的最新进展与未来方向

Recent Advances and Future Directions in Sonodynamic Therapy for Cancer Treatment.

靶向 IL-13Rα2 的肿瘤免疫治疗最新进展

Recent Advances in IL-13Rα2-Directed Cancer Immunotherapy.

2009 至 2021 年 CAR-T 细胞的文献计量学与知识图谱分析

A Bibliometric and Knowledge-Map Analysis of CAR-T Cells From 2009 to 2021.

作为一种具有巨大潜力和临床应用前景的抗肿瘤疗法，CAR-T 细胞疗法仍处于快速发展阶段。CAR-T 细胞相关领域在未来仍将是研究热点。